UCBJF Stock News Ucb S A (UCBJF) 85.9416 07/25/2014 09:42:34

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ucb S A (UCBJF) 85.9416 $UCBJF

UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:40PM CDT
UCB SA (UCBJF) announced positive top-line results from a phase III study on epilepsy candidate, brivaracetam.

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.

Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
M2 - Mon May 26, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6m5p4d/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include - AbbVie Inc. - Galderma S.A. - Johnson & Johnson Ltd. - Novartis AG - Stiefel Laboratories Inc. - Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are - Actavis plc - Allergan Inc. - Almirall SA - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc - Bayer AG - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - Genentech Inc. - Incyte Corp. - Isotechnika Inc. - LEO Pharma A/S - Merck & Co. Inc. - Mylan Pharmaceuticals Inc. - Pfizer Inc. - UCB SA. Key questions answered in this report: - What will the market size and growth rate be in 2018? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? For more information visit http://www.researchandmarkets.com/research/6m5p4d/global

Update on Pfizer's OTC Nexium 24HR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:30PM CDT
Pfizer announced that it has received the FDA approval for its OTC version of AstraZeneca's Nexium 24HR.

Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.

UCB to Return Tozadenant Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 4:44PM CDT
UCB announced that it will return global rights to tozadenant (SYN115) to Biotie Therapies Corp.

Sanofi, UCB Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 5:10PM CDT
Sanofi entered into an agreement with UCB for the discovery and development of therapies for immune-mediated diseases including gastroenterology and arthritis.

UCB Misses Earnings Ests, Revs In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 12:32PM CST
UCB reported 2013 earnings per share of $2.56, missed the Zacks Consensus Estimate of $2.84.

UCB : CONVENING NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Thomson Reuters ONE - Fri Feb 21, 2:01AM CST
The shareholders are invited to attend the Extraordinary General Meeting which will be held on Monday, 24 March 2014, at 09:00 am CET at the registered office of UCB SA/NV, Allee de la Recherche 60 - 1070 Brussels, for the purpose of considering the items shown on the agenda set out below.

Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine

CHMP Positive on Roche's RoActemra's Subcutaneous Formulation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 23, 9:50AM CST
Roche recently received positive news when the Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on the subcutaneous formulation of rheumatoid arthritis (RA) drug RoActemra.

Loss Narrows at Immunomedics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 26, 8:54AM CDT
Immunomedics reported fourth quarter 2013 loss of 9 cents per share.

Good News for RedHill Biopharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 23, 3:10PM CDT
Good news flowed in at RedHill Biopharma when the company received a positive feedback on its RHB-104.

Another Generic Launch at Mylan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 16, 9:50AM CDT
Mylan launched its generic version of Abbott Labs' Trilipix.

New Data on UCB's Cimzia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 14, 2:48PM CDT
UCB presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia at the European League Against Rheumatism (EULAR) Congress.

Update on UCB Lupus Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 13, 8:40PM CDT
UCB recently presented new data on its lupus candidate, epratuzumab, from an open-label extension study of the EMBLEM phase IIb study
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 69

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading

Top 5 Most Recently Viewed Articles

An In-Depth Analysis of Qorvo's Current Short Interest Trends

Updated Category News Views 215

Understanding Qorvo's Short Interest Movement Qorvo Inc. (NASDAQ: QRVO) has been experiencing notable changes in its short interest, with a recent report indicating a decrease of 16.17%. This drop reflects a total of 5.20 million shares sold short, equating to about 7.67% of the total shares available for trading. Traders should note that, with the current trading volume,...

Continue Reading
Sev1Tech Secures $188M Contract with U.S. Space Force

Updated Category News Views 167

Sev1Tech Secures a Major Contract with the U.S. Space Force Sev1Tech has recently made headlines by being awarded a substantial contract valued at $188 million from the U.S. Space Force (USSF), specifically under the Space Systems Command (SSC). This contract involves expanding the support for an innovative and powerful network known as meshONE-T. This network is...

Continue Reading
Exploring Rigetti Computing's Growth and ETF Impact

Updated Category News Views 339

Understanding the Surge of Rigetti Computing Rigetti Computing Inc. (NASDAQ: RGTI) has seen an extraordinary performance recently, with its shares rising a staggering 100% year-to-date, and almost 3,900% over the past year. This impressive increase has attracted considerable investor interest, particularly from those focused on opportunities in the rapidly evolving...

Continue Reading
Kratos Defense Stock Climbs High: What Investors Should Know

Updated Category News Views 198

Kratos Defense Stock Reaches New Heights Kratos Defense (NASDAQ: KTOS) has recently achieved a remarkable milestone by hitting a 52-week high of $30.42. This achievement comes amid a strong defense market, marking a significant increase in the company's stock value with a one-year growth of 55.96%. Investors demonstrate growing confidence in Kratos, renowned for its...

Continue Reading
Precision Linear Actuators for Optical and Automation Needs

Updated Category News Views 143

High-Precision Micro-Positioning Solutions Available For those seeking reliability and accuracy in optical alignment, precision automation, and research applications, the latest offerings from PI deliver exceptional results. Introducing the L-220 Series Linear Actuators PI’s L-220 series linear actuators are designed for applications demanding sub-micrometer precision....

Continue Reading